{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:06:38Z","timestamp":1792710398834,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.canlet.2024.216642","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T09:02:24Z","timestamp":1706086944000},"page":"216642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Inhibition of ATM promotes PD-L1 expression by activating JNK\/c-Jun\/TNF-\u03b1 signaling axis in triple-negative breast cancer"],"prefix":"10.1016","volume":"586","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5743-0092","authenticated-orcid":false,"given":"Chenying","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5501-1848","authenticated-orcid":false,"given":"Chunyan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjie","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangshen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanming","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqin","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1825-2903","authenticated-orcid":false,"given":"Weimin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3753-2900","authenticated-orcid":false,"given":"Xiaojing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2024.216642_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.1049741","article-title":"Gene expression profile analysis to discover molecular signatures for early diagnosis and therapies of triple-negative breast cancer","volume":"9","author":"Alam","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.canlet.2024.216642_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2024.216642_bib3","doi-asserted-by":"crossref","first-page":"111720","DOI":"10.1016\/j.ejmech.2019.111720","article-title":"Dual-targeting liposomes with active recognition of GLUT(5) and alpha(v)beta(3) for triple-negative breast cancer","volume":"183","author":"Pu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.canlet.2024.216642_bib4","doi-asserted-by":"crossref","first-page":"657634","DOI":"10.3389\/fonc.2021.657634","article-title":"Efficacy and safety of adding immune checkpoint inhibitors to neoadjuvant chemotherapy against triple-negative breast cancer: a meta-analysis of randomized controlled trials,","volume":"11","author":"Li","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2024.216642_bib5","doi-asserted-by":"crossref","first-page":"1004821","DOI":"10.3389\/fphar.2022.1004821","article-title":"Predictive value of PD-L1 expression to the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer: a systematic review and meta-analysis,","volume":"13","author":"Qi","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2024.216642_bib6","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2024.216642_bib7","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.216642_bib8","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.216642_bib9","doi-asserted-by":"crossref","first-page":"103662","DOI":"10.1016\/j.drudis.2023.103662","article-title":"Targeting ATM and ATR for cancer therapeutics: inhibitors in clinic","volume":"28","author":"Priya","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.canlet.2024.216642_bib10","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1186\/s12967-023-04312-2","article-title":"Ketoglutaric acid can reprogram the immunophenotype of triple-negative breast cancer after radiotherapy and improve the therapeutic effect of anti-PD-L1","volume":"21","author":"Tan","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2024.216642_bib11","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41586-023-06069-6","article-title":"The complementarity of DDR, nucleic acids and anti-tumour immunity,","volume":"619","author":"Kornepati","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.216642_bib12","doi-asserted-by":"crossref","first-page":"875648","DOI":"10.3389\/fimmu.2022.875648","article-title":"DNA damage response evaluation provides novel insights for personalized immunotherapy in glioma","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2024.216642_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143415","article-title":"Intersection of two checkpoints: could inhibiting the DNA damage response checkpoint rescue immune checkpoint-refractory cancer?","volume":"13","author":"Goff","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2024.216642_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14225633","article-title":"Role of PARP inhibitors in cancer immunotherapy: potential friends to immune activating molecules and foes to immune checkpoints","volume":"14","author":"Franzese","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2024.216642_bib15","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s13046-022-02469-0","article-title":"The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy,","volume":"41","author":"Shi","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216642_bib16","doi-asserted-by":"crossref","first-page":"1073797","DOI":"10.3389\/fmolb.2022.1073797","article-title":"The potential of PARP inhibitors in targeted cancer therapy and immunotherapy,","volume":"9","author":"Hunia","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.canlet.2024.216642_bib17","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1158\/1078-0432.CCR-20-0056","article-title":"Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study","volume":"26","author":"Lampert","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216642_bib18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40265-019-01249-z","article-title":"Novel therapeutics for recurrent cervical cancer: moving towards personalized therapy","volume":"80","author":"Cohen","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.canlet.2024.216642_bib19","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2024.216642_bib20","article-title":"Targeted therapies and the evolving standard of Care for triple-negative and germline BRCA1\/2-mutated breast cancers in the high-risk, early-stage setting","volume":"7","author":"Desai","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.canlet.2024.216642_bib21","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.3724\/abbs.2022153","article-title":"Triple kill: DDR inhibitors, radiotherapy and immunotherapy leave cancer cells with no escape","volume":"54","author":"Qiu","year":"2022","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.canlet.2024.216642_bib22","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1021\/acsmedchemlett.3c00034","article-title":"Discovery of [1,2,3]Triazolo[4,5-c]quinoline derivatives as a new class of ataxia-telangiectasia mutated kinase inhibitors","volume":"14","author":"Zhang","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.canlet.2024.216642_bib23","series-title":"Activation of Sting in Response to Partial-Tumor Radiation Exposure, Int J Radiat Oncol Biol Phys","author":"Mathieu","year":"2023"},{"key":"10.1016\/j.canlet.2024.216642_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15123259","article-title":"The histological background of recurrence in laryngeal squamous cell carcinoma: an insight into the modifications of tumor microenvironment,","volume":"15","author":"Arcovito","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2024.216642_bib25","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/jmcb\/mjs048","article-title":"Activation of the ATM-Snail pathway promotes breast cancer metastasis","volume":"4","author":"Sun","year":"2012","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2024.216642_bib26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014,","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2024.216642_bib27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10549-022-06679-0","article-title":"STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression","volume":"196","author":"Song","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2024.216642_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051307","article-title":"Single-cell transcriptomic analysis of tumor-derived fibroblasts and normal tissue-resident fibroblasts reveals fibroblast heterogeneity in breast cancer","volume":"12","author":"Sebastian","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2024.216642_bib29","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.1140321","article-title":"ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage","volume":"316","author":"Matsuoka","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.canlet.2024.216642_bib30","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1038\/s41388-021-01746-0","article-title":"Tumor resistance to radiotherapy is triggered by an ATM\/TAK1-dependent-increased expression of the cellular prion protein","volume":"40","author":"Bernardino-Sgherri","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2024.216642_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.203","article-title":"Glucolipotoxicity initiates pancreatic beta-cell death through TNFR5\/CD40-mediated STAT1 and NF-kappaB activation","volume":"7","author":"Bagnati","year":"2016","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2024.216642_bib32","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ccell.2016.10.010","article-title":"Deubiquitination and stabilization of PD-L1 by CSN5","volume":"30","author":"Lim","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216642_bib33","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/cdd.2016.162","article-title":"STAT1 mediates transmembrane TNF-alpha-induced formation of death-inducing signaling complex and apoptotic signaling via TNFR1","volume":"24","author":"Jiang","year":"2017","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2024.216642_bib34","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1128\/MCB.16.2.459","article-title":"Tumor necrosis factor alpha gene regulation in activated T cells involves ATF-2\/Jun and NFATp","volume":"16","author":"Tsai","year":"1996","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2024.216642_bib35","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1128\/MCB.16.10.5232","article-title":"Cell-type-specific regulation of the human tumor necrosis factor alpha gene in B cells and T cells by NFATp and ATF-2\/JUN","volume":"16","author":"Tsai","year":"1996","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2024.216642_bib36","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.molcel.2004.10.024","article-title":"Identification of promoters bound by c-Jun\/ATF2 during rapid large-scale gene activation following genotoxic stress","volume":"16","author":"Hayakawa","year":"2004","journal-title":"Mol Cell"},{"key":"10.1016\/j.canlet.2024.216642_bib37","doi-asserted-by":"crossref","first-page":"8736","DOI":"10.1158\/0008-5472.CAN-04-2584","article-title":"The prosurvival activity of p53 protects cells from UV-induced apoptosis by inhibiting c-Jun NH2-terminal kinase activity and mitochondrial death signaling,","volume":"64","author":"Lo","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.216642_bib38","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3389\/fphar.2020.00343","article-title":"The drug-resistance mechanisms of five platinum-based antitumor agents,","volume":"11","author":"Zhou","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2024.216642_bib39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/B978-0-12-380888-2.00003-0","article-title":"The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer,","volume":"108","author":"Smith","year":"2010","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216642_bib40","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/S0140-6736(16)32454-0","article-title":"Molecular alterations in triple-negative breast cancer-the road to new treatment strategies","volume":"389","author":"Denkert","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2024.216642_bib41","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/path.5406","article-title":"G. International Immuno-Oncology Biomarker Working, the path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice,","volume":"250","author":"Gonzalez-Ericsson","year":"2020","journal-title":"J. Pathol."},{"key":"10.1016\/j.canlet.2024.216642_bib42","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/SLA.0000000000004303","article-title":"Comprehensive molecular characterization of adenocarcinoma of the gastroesophageal junction between esophageal and gastric adenocarcinomas","volume":"275","author":"Suh","year":"2022","journal-title":"Ann. Surg."},{"key":"10.1016\/j.canlet.2024.216642_bib43","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature18294","article-title":"Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers","volume":"534","author":"Kataoka","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.216642_bib44","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jtho.2015.09.010","article-title":"PD-L1 is upregulated by simultaneous amplification of the PD-L1 and JAK2 genes in non-small cell lung cancer","volume":"11","author":"Ikeda","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2024.216642_bib45","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw283","article-title":"The MLL1-H3K4me3 axis-mediated PD-L1 expression and pancreatic cancer immune evasion,","volume":"109","author":"Lu","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2024.216642_bib46","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.celrep.2017.02.011","article-title":"BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1","volume":"18","author":"Hogg","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2024.216642_bib47","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2024.216642_bib48","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.imlet.2017.02.006","article-title":"Inflammatory cytokines IL-17 and TNF-alpha up-regulate PD-L1 expression in human prostate and colon cancer cells","volume":"184","author":"Wang","year":"2017","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.canlet.2024.216642_bib49","article-title":"Helicobacter pylori promote B7-H1 expression by suppressing miR-152 and miR-200b in gastric cancer cells","volume":"12","author":"Xie","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2024.216642_bib50","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.immuni.2017.11.016","article-title":"Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA","volume":"47","author":"Coelho","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2024.216642_bib51","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nm1517","article-title":"Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma","volume":"13","author":"Parsa","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2024.216642_bib52","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1053\/j.gastro.2019.01.252","article-title":"MET inhibitors promote liver tumor evasion of the immune response by stabilizing PDL1","volume":"156","author":"Li","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2024.216642_bib53","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1172\/JCI126022","article-title":"IL-6\/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion","volume":"129","author":"Chan","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2024.216642_bib54","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1084\/jem.20180870","article-title":"Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer","volume":"216","author":"Gong","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2024.216642_bib55","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cell.2019.02.016","article-title":"Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory","volume":"177","author":"Poggio","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2024.216642_bib56","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000289196","article-title":"Transcriptional control of the TNF gene","volume":"11","author":"Falvo","year":"2010","journal-title":"Curr. Dir. Autoimmun."},{"key":"10.1016\/j.canlet.2024.216642_bib57","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrm3546","article-title":"The ATM protein kinase: regulating the cellular response to genotoxic stress, and more,","volume":"14","author":"Shiloh","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2024.216642_bib58","first-page":"1307","article-title":"Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing","volume":"8","author":"Sun","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216642_bib59","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1158\/0008-5472.CAN-19-0761","article-title":"Inhibition of ATM increases interferon signaling and sensitizes pancreatic cancer to immune checkpoint blockade therapy","volume":"79","author":"Zhang","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.216642_bib60","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41467-017-01883-9","article-title":"DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells","volume":"8","author":"Sato","year":"2017","journal-title":"Nat. Commun."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524000363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524000363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:13:21Z","timestamp":1759594401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524000363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":60,"alternative-id":["S0304383524000363"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216642","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of ATM promotes PD-L1 expression by activating JNK\/c-Jun\/TNF-\u03b1 signaling axis in triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216642","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"216642"}}